JNJ-55308942
JNJ-55308942 is an investigational drug that works as a P2X7 antagonist with a downstream effect of reducing interleukin-1β release. It is developed by Janssen Pharmaceuticals for bipolar depression.
JNJ-55308942 is an investigational drug that works as a P2X7 antagonist with a downstream effect of reducing interleukin-1β release. It is developed by Janssen Pharmaceuticals for bipolar depression.